Overview

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

Status:
Completed
Trial end date:
2019-08-21
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Phase:
Phase 2
Details
Lead Sponsor:
Akcea Therapeutics
Collaborator:
Ionis Pharmaceuticals, Inc.